To include your compound in the COVID-19 Resource Center, submit it here.

CFDA reviewing roxadustat, FibroGen gets $15M payday

FibroGen Inc. (NASDAQ:FGEN) said China FDA accepted for review an NDA for roxadustat (FG-4592) to treat

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE